A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

• Status: Not yet recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to find out more about the drug treprostinil via inhaler and the mechanisms of why patients with pulmonary arterial hypertension related to Interstitial Lung disease (PAH-ILD) have limitations during exercise. The investigator is studying treprostinil's effect on patients with PAH-ILD during exercise and its effect on their quality of life after using it for 3 months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: United Therapeutics
• Treatments: Treprostinil

Criteria

Inclusion Criteria:

• ≥ 18 Years of Age

• Patients with suspected Pulmonary Arterial Hypertension related to Interstitial Lung Disease (ILD-PAH) undergoing right heart catheterization.

• Undergoing cardiac catheterization for clinical indications at Mayo Clinic Rochester over a 12-month period.

• Healthy volunteers will have no known lung disease, heart failure, muscular disease or pulmonary hypertension

Exclusion Criteria:

• < 18 years old.